MAPK Signaling
Research Areas
Products Related to MAPK Signaling(660)
- GC17031VRT752271CAS: 869886-67-9Purity: >99.50%
VRT752271 (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. VRT752271 (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.
- GC13001SB 203580 hydrochlorideCAS: 869185-85-3Purity: >98.00%
Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively.
- GC13968SB202190 (FHPI)CAS: 152121-30-7Purity: >99.00%
SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC16872 | Refametinib | 923032-37-5 | >99.50% | |
MEK 1/ MEK 2 inhibitor | ||||
| GC17031 | VRT752271 | 869886-67-9 | >99.50% | |
VRT752271 (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. VRT752271 (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line. | ||||
| GC10647 | FR 180204 | 865362-74-9 | >98.00% | |
FR 180204 is a selective ERK inhibitor with IC 50 values of 0.51μM and 0.33μM for ERK1 and ERK2, respectively. | ||||
| GC13001 | SB 203580 hydrochloride | 869185-85-3 | >98.00% | |
Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. | ||||
| GC13968 | SB202190 (FHPI) | 152121-30-7 | >99.00% | |
SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. | ||||
| GC10204 | AEG 3482 | 63735-71-7 | >99.00% | |
inhibitor of Jun kinase (JNK)-dependent apoptosis | ||||
| GC10534 | B-Raf IN 1 | 950736-05-7 | >98.50% | |
B-Raf inhibitor | ||||
| GC12321 | PKI 14-22 amide, myristoylated | 201422-03-9 | >98% | |
PKA inhibitor | ||||
| GC12674 | IQ 3 | 312538-03-7 | >98.50% | |
Selective JNK3 inhibitor | ||||
| GC12904 | BI 78D3 | 883065-90-5 | >99.00% | |
Competitive JNK inhibitor | ||||
| GC13717 | Losmapimod | 585543-15-3 | >98.00% | |
p38 MAPK inhibitor, orally active | ||||
| GC14648 | KT 5720 | 108068-98-0 | >98.00% | |
protein kinase A inhibitor, potent and selective | ||||